Pharmacognostic Evaluation of Parmelia sulcata Taylor and its Cytotoxic Effects on a Glioblastoma Cell Line

ABSTRACT

Objectives: The current study aims to establish the pharmacognostic profile and evaluate the cytotoxic potential of Parmelia sulcata Talyor in the glioblastoma cell line. Materials and Methods: In this experimental investigation, pharmacognostic evaluation has been conducted via standard procedures, and active fractions obtained through column chromatography, further identified by liquid chromatography– mass spectrometry (LC–MS). The total antioxidant capacity of the ethanolic extract of the lichen was obtained via the phosphomolybdate method, and a reducing power assay was conducted to determine its in vitro antioxidant potential. The glioblastoma U87-MG cell lines were cultivated in minimum essential medium supplemented with nonessential amino acids, and 10% fetal bovine serum was maintained under controlled conditions. 3-(4,5-Dimethyl thiazolyl-2)-2,5-diphenyltetrazolium bromide assay was used to test the cytotoxicity of ethanolic extract of lichen and its isolated active fraction. Results: The pharmacognostic profile of P. sulcata inhabiting in lithophytic life form has been established. Morphological parameters aided in studying the physical attributes of lichen, whereas microscopic parameters helped to determine the histological characteristics. LC–MS analysis of purified fractions confirms the presence of phenolics in the lichens responsible for anticancer activity. Pharmacological data on U87-MG cell lines revealed the possible usage of this lichen in the treatment of glioblastoma and its associated pathological conditions. Lichen extract and its purified fraction (L16–L21) significantly (p < 0.05) inhibited the proliferation of U87 glioblastoma cells in a dose-dependent manner. Conclusion: This study reported that the shield lichen has promising cytotoxic activities in U87-MG cell lines, which was marked by a reduction in cancer cell proliferation. Further pharmacognostic and phytochemical data confirmed its identity and facilitated its inclusion in various Pharmacopoeias.

KEYWORDS

• Shield lichen
• Parmelia sulcata
• glioblastoma
• U87-MG

Showing references and in-text citations exactly as published.

Cite this article

• DOI10.1177/0976500X241303567Copy

RELATED ARTICLES

Matched on section and article type within this issue of J Pharmacol. Pharmacother..

• Article · VOLUME 16, ISSUE 4Assessing the Anticancer Potential of Compounds from Caesalpinia sappan Wood against Mutant EGFR in Lung Squamous Cell Carcinoma: Computational InsightsShaik Pashmina, Nitya Krishnasamy, Suganya Panneer Selvam, Ramya Ramadoss, Sandhya Sundar · pp. 375–385Original Research ArticleSame type: Article
• Article · VOLUME 16, ISSUE 4A Novel Non-invasive Approach, “DrOroscope,” for Early Detection of Dysplasia in Oral Mucosal Lesions: A Cross-sectional StudyMounika Yeladandi, T. N. Uma Maheswari, Swetha Bindu Padala, Mekala Mary Sujatha, Harika Vemula, Tejaswi Kala, Mohammed Abidullah · pp. 386–394Original Research ArticleSame type: Article
• Article · VOLUME 16, ISSUE 4Hypolipidemic and Hepatoprotective Effect of Linum usitatissimum and Moringa oleifera Seeds in Diabetic Induced Damage in RatsNitu Sahoo, Dillip Kumar Bishi, Vartika Srivastava, Chaitali Pattanayak, Sougata Sarkar · pp. 395–401Original Research ArticleSame type: Article
• Article · VOLUME 16, ISSUE 4Pharmaceutical Frontliners: Community Pharmacists’ Contribution to Managing Medication Needs During a Health Crisis— The COVID-19 Era as an ExampleNoor R. Al-Hasani, Fadya Y. Al-Hamadani, Dhulfiqar N. Alhilali, Ali Azeez Al-Jumaili, Faaiz Y. Alhamdani · pp. 402–411Original Research ArticleSame type: Article